Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Medicago and GSK Announce the Approval by Health Canada of COVIFENZ ®, an Adjuvanted Plant-based COVID-19 Vaccine
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health […]
SeekIn Receives CE Mark Approval for SeekInCare® Pan Cancer Early Detection Test
SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the […]
US FDA Approves Jardiance ® (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction
The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg to […]
Evaluating the Effects of ACE2-Mediated Covid-19 Infection
Covid-19 has impacted virtually everyone‘s lives, whether through personal experience of infection or the impacts […]
NHS Treats First Sickle Cell Disease Patients With Life-Changing Drug
One of the first patients to access a ground-breaking treatment for sickle cell disease on […]
BIORCHESTRA Announces 45 Million USD Series C Fundraising
BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using […]
BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Medigene AG (FSE: MDG1, Prime Standard, “Medigene”), a clinical-stage immuno-oncology company focusing […]
Whole Genome Sequencing Robustly Detects the Most Common Inherited Neurological Diseases and is Adopted by Healthcare
Scientists have found whole genome sequencing (WGS) can quickly and accurately detect the most common […]
Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-stage Heart Failure
Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded […]
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin’s Lymphoma
Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more